摘要
脯氨酸脱氢酶/脯氨酸氧化酶(PRODH / POX)是一种催化脯氨酸第一步降解的酶,过程中产生ROS和ATP。POX广泛分布于生物体中,并负责一些调节过程,如氧化还原稳态,渗透调节,细胞信号和氧化应激。最近数据表明,POX在肿瘤发生和肿瘤生长中起着重要的作用。POX可通过内在和外在的方式诱导细胞凋亡。由于ROS的产生,POX可诱导caspase-9活性,其可介导线粒体凋亡(内源性凋亡途径)。POX也能刺激TRAIL(肿瘤坏死因子相关凋亡诱导配体)和DR5(死亡受体5)的表达,导致procaspase-8裂解和外源性凋亡。然而,这种抑癌基因在一定环境条件下可作为一种促生存因子,但遗传毒性,炎症和代谢应激可能使POX从抑制肿瘤生长转为促进肿瘤生长。本文将讨论可以调节切换POX模式的潜在机制。
关键词: 细胞凋亡,癌,脯氨酸脱氢酶(PRODH),脯氨酸氧化酶(POX)。
图形摘要
Current Drug Targets
Title:Proline Oxidase (POX) as A Target for Cancer Therapy
Volume: 16 Issue: 13
Author(s): Joanna Kononczuk, Urszula Czyzewska, Joanna Moczydlowska, Arkadiusz Surażyński, Jerzy Palka and Wojciech Miltyk
Affiliation:
关键词: 细胞凋亡,癌,脯氨酸脱氢酶(PRODH),脯氨酸氧化酶(POX)。
摘要: Proline dehydrogenase/proline oxidase (PRODH/POX) is an enzyme catalyzing the first step of proline degradation, during which ROS and/or ATP is generated. POX is widely distributed in living organisms and is responsible for a number of regulatory processes such as redox homeostasis, osmotic adaptation, cell signaling and oxidative stress. Recent data provided evidence that POX plays an important role in carcinogenesis and tumor growth. POX may induce apoptosis in both intrinsic and extrinsic way. Due to ROS generation, POX may induce caspase-9 activity, which mediates mitochondrial apoptosis (intrinsic apoptosis pathway). POX can also stimulate TRAIL (tumor necrosis factorrelated apoptosis inducing ligand) and DR5 (death receptor 5) expression, resulting in cleavage of procaspase-8 and thus extrinsic apoptotic pathway. However, this tumor suppressor in certain environmental conditions may act as a prosurvival factor. Genotoxic, inflammatory and metabolic stress may switch POX from tumor growth inhibiting to tumor growth supporting factor. The potential mechanisms which may regulate switching of POX mode are discussed in this review.
Export Options
About this article
Cite this article as:
Joanna Kononczuk, Urszula Czyzewska, Joanna Moczydlowska, Arkadiusz Surażyński, Jerzy Palka and Wojciech Miltyk , Proline Oxidase (POX) as A Target for Cancer Therapy, Current Drug Targets 2015; 16 (13) . https://dx.doi.org/10.2174/138945011613151031150637
DOI https://dx.doi.org/10.2174/138945011613151031150637 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development
Current Cancer Drug Targets Evaluation of a New <sup>99m</sup>Tc-labeled GnRH Analogue as a Possible Imaging Agent for Prostate Cancer Detection
Anti-Cancer Agents in Medicinal Chemistry New Generation of Liposomes Called Archaeosomes Based on Natural or Synthetic Archaeal Lipids as Innovative Formulations for Drug Delivery
Recent Patents on Drug Delivery & Formulation Cyclodextrin Based Nanosponges: Impending Carters in Drug Delivery and Nanotherapeutics
Current Drug Therapy Macrocyclic Inhibitors of Hsp90
Current Topics in Medicinal Chemistry Multifunctional Mesoporous Silica Nanoparticles for Combined Therapeutic, Diagnostic and Targeted Action in Cancer Treatment
Current Drug Targets Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism Evaluation and Exploitation of Bioactive Compounds of Walnut, Juglans regia
Current Pharmaceutical Design Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery
Current Pharmaceutical Design Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach
Current Molecular Medicine Nanoplatforms for Promoting Osteogenesis in Ovariectomy-Induced Osteoporosis in the Experimental Model
Current Nanomedicine LDH Nanocontainers as Bio-Reservoirs and Drug Delivery Carriers
Recent Patents on Nanotechnology Potentialities of Induced Pluripotent Stem (iPS) Cells for Treatment of Diseases
Current Molecular Medicine PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease
Current Chemical Biology Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry The Effect of Proton Pump Inhibitors on the Human Microbiota
Current Drug Metabolism Current Drug Design Strategies for Fighting Against Swine Influenza
Current Drug Therapy